Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

Access new research on IRLAB by equity research company Edison!

Access here >

Latest press release

IRLAB announces that equity research company Edison initiates coverage of the company

June 2, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that equity research company Edison Investment Research has been engaged by IRLAB to produce regular, in-depth research on the company. The intention is to raise the visibility of the company and enable investors and stakeholders to develop an improved understanding of the business.

Read More >
Latest presentation

CEO Nicholas Waters, CEO, participated at Redeye Growth Day 2021

June 2, 2021

Nicholas Waters, CEO, presented at Redeye Growth Day on June 2, 2021. The presentationen is followed by a Q&A and is held in English. Watch here >

Read More >

Subscribe